Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10570700 | 0.92 | CTSK (0.54) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL5413813 | 0.90 | TRPM8 (0.56) | CTSKCTSSCTSLCTSBACE2 | |
| SCHEMBL4910315 | 0.90 | TRPM8 (0.56) | CTSKCTSSCTSLCTSBACE2 | |
| SCHEMBL24324236 | 0.90 | TRPM8 (0.56) | CTSKCTSSCTSLCTSBACE2 | |
| SCHEMBL7698179 | 0.90 | TRPM8 (0.56) | CTSKCTSSCTSLCTSBACE2 | |
| SCHEMBL8478010 | 0.85 | CTRB1 (0.54) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL10559587 | 0.85 | CTSK (0.55) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL3042938 | 0.85 | CTSK (0.57) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL29865843 | 0.85 | CTSK (0.57) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL3042936 | 0.85 | CTSK (0.57) | CTSKCTSSCTSLCTSBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210603-A1 | NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | TUNG ROGER D | 2010-08-19 | — | — | US | disclosed |
| US-7608632-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080293727-A1 | Novel sulfonamide inhibitors of aspartyl protease | TUNG ROGER D | 2008-11-27 | — | — | US | disclosed |
| US-7321063-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-22 | — | — | US | disclosed |
| US-20060189810-A1 | Novel sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-24 | — | — | US | disclosed |
| US-20040167116-A1 | Novel sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| US-6720335-B2 | VIRICIDES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-04-13 | — | — | US | disclosed |
| EP-0885887-B1 | Sulfonamide inhibitors of HIV-Aspartyl protease | VERTEX PHARMA (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030069222-A1 | Novel sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| US-20030064977-A1 | Novel sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| EP-0846110-B1 | THF-CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6392046-B1 | AIDS THERAPY | VERTEX PHARMACEUTICALS, INC. | 2002-05-21 | — | — | US | disclosed |
| US-6372778-B1 | AMINE HYDROXYALKYL SULFONAMIDE AS ENZYME INHIBITORS | VERTEX PHARMACEUTICALS, INCORPORATED | 2002-04-16 | — | — | US | disclosed |
| EP-0885887-A2 | Sulfonamide inhibitors of HIV-Aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0846110-A1 | THF-CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1996033184-A1 | THF-CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069222-A1 | Novel sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CTSK 231/4885CTSS 47/4885CTSL 68/4885 |
| US-20040167116-A1 | Novel sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CTSK 231/4885CTSS 47/4885CTSL 68/4885 |
| US-20100210603-A1 | NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | SPINT2, PRSS1, DNPEP | CTSK 231/4885CTSS 47/4885CTSL 68/4885 |
| US-20030064977-A1 | Novel sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CTSK 231/4885CTSS 47/4885CTSL 68/4885 |
| US-20060189810-A1 | Novel sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CTSK 231/4885CTSS 47/4885CTSL 68/4885 |
| US-20080293727-A1 | Novel sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CTSK 231/4885CTSS 47/4885CTSL 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.